A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)
24 września 2018 zaktualizowane przez: Merck Sharp & Dohme LLC
A Crossover Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG)
The purpose of this randomized, double-blind, placebo-controlled, 5-period crossover study is to assess the effect of single oral doses of MK-1064 on latency to persistent sleep (LPS) as measured by polysomnography (PSG) in healthy young male participants, and to evaluate the safety and tolerability of single oral doses of MK-1064 and MK-6096 in healthy young male participants.
The primary efficacy hypothesis is that at least one dose of MK-1064 is superior to placebo in decreasing LPS in healthy male participants as assessed by PSG.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
20
Faza
- Faza 1
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat do 45 lat (Dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Męski
Opis
Inclusion Criteria:
- Body Mass Index (BMI) ≤31 kg/m^2
- In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests
- Nonsmoker and has not used nicotine or nicotine-containing products for at least 6 months
- No history of any sleep disorder
- Has not used prescription or over the counter sedation or alerting medication in 4 weeks prior to screening
- Participant has a usual bedtime between 8:00 PM and 12:00 AM
- Participant has total sleep duration of ≥6.5 and ≤9 hours during the 4 weeks prior to screening
- Male participants with female partner(s) of child-bearing potential must agree to use a medically acceptable method of contraception during the study and for 90 days after the last dose of study drug
Exclusion Criteria:
- Mentally or legally incapacitated, significant emotional problems at screening or expected during the conduct of the study or history of a clinically significant psychiatric disorder within the last 10 years
- History of any persistent sleep abnormality (including difficulty falling asleep, difficulty staying asleep) lasting for 3 months or more, or history of obstructive sleep apnea, restless leg syndrome, or narcolepsy
- History of clinically significant sleep disorders within the last 5 years
- History of circadian rhythm sleep disorder, clinically important parasomnia, or primary insomnia
- History of repeated falls or fractures secondary to falling within the past 2 years
- Participant works a night shift and is not able to avoid night shift work a minimum of 1 week prior to screening and for the duration of the study
- Participant has traveled across 3 or more time zones (transmeridian travel) in the last 2 weeks prior to study
- Is a regular user of sedative-hypnotic agents
- History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
- History of stroke, peripheral neuropathy, chronic seizures or other clinically significant neurological disorder or cognitive impairment
- History of cancer
- History of cataplexy
- Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies, beginning approximately 2 weeks prior to administration of the initial dose of study drug and throughout the study
- Participant consumes >3 servings of alcohol a day
- Participant consumes >6 caffeine servings a day
- Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to screening, or participated in another investigational study within 3 months prior to first dose of study drug
- History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
- Is currently a regular user of any illicit drugs or has a history of drug (including alcohol) abuse within 2 years of screening
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
|
Eksperymentalny: Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
|
Eksperymentalny: Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
|
Eksperymentalny: Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Latency to Persistent Sleep (LPS) Following Single Doses of MK-1064 and Placebo
Ramy czasowe: 1 to 9 hours post dose, within each treatment period
|
LPS is measured during overnight sleep laboratory (polysomnography [PSG]) assessment and is defined as the duration of time from the beginning of PSG assessment to the first interval of 10 consecutive minutes of sleep.
|
1 to 9 hours post dose, within each treatment period
|
|
LPS Following Single Doses of MK-6096 and Placebo
Ramy czasowe: 1 to 9 hours post dose, within each treatment period
|
LPS is measured during overnight sleep laboratory (PSG) assessment and is defined as the duration of time from the beginning of PSG assessment to the first interval of 10 consecutive minutes of sleep.
|
1 to 9 hours post dose, within each treatment period
|
|
Number of Participants With Adverse Events (AEs)
Ramy czasowe: Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study drug, is also an AE.
|
Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
|
Number of Participants Who Discontinued Study Due to an AE
Ramy czasowe: Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study drug, is also an AE.
|
Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Wake Time After Sleep Onset (WASO) Following Single Doses of MK-1064 and Placebo
Ramy czasowe: 1 to 9 hours post dose, within each treatment period
|
WASO is measured during overnight sleep laboratory (PSG) assessment and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning.
|
1 to 9 hours post dose, within each treatment period
|
|
WASO Following Single Doses of MK-6096 and Placebo
Ramy czasowe: 1 to 9 hours post dose, within each treatment period
|
WASO is measured during overnight sleep laboratory (PSG) assessment and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning.
|
1 to 9 hours post dose, within each treatment period
|
|
Change From Baseline in Choice Reaction Time (CRT) Following Single Doses of MK-1064 and Placebo
Ramy czasowe: Pre-dose and 10 hours post dose, within each treatment period
|
CRT assessment used in this study is a two-choice, computer-controlled test in which the participant responds to stimulus words presented on the screen of a laptop computer.
During the test either the word "NO" or the word "YES" is presented on the screen and the participant is instructed to press the corresponding button as quickly as possible.
There are 50 trials for which each stimulus word is chosen randomly with equal probability and there is a varying inter-stimulus interval.
The mean reaction time of accurate responses is determined.
The assessment is performed pre-dose and at 10 hours post dose.
The outcome measure is change from baseline to post dose in reaction time.
|
Pre-dose and 10 hours post dose, within each treatment period
|
|
Change From Baseline in CRT Following Single Doses of MK-6096 and Placebo
Ramy czasowe: Pre-dose and 10 hours post dose, within each treatment period
|
CRT assessment used in this study is a two-choice, computer-controlled test in which the participant responds to stimulus words presented on the screen of a laptop computer.
During the test either the word "NO" or the word "YES" is presented on the screen and the participant is instructed to press the corresponding button as quickly as possible.
There are 50 trials for which each stimulus word is chosen randomly with equal probability and there is a varying inter-stimulus interval.
The mean reaction time of accurate responses is determined.
The assessment is performed pre-dose and at 10 hours post dose.
The outcome measure is change from baseline to post dose in reaction time.
|
Pre-dose and 10 hours post dose, within each treatment period
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
6 listopada 2009
Zakończenie podstawowe (Rzeczywisty)
6 kwietnia 2010
Ukończenie studiów (Rzeczywisty)
6 kwietnia 2010
Daty rejestracji na studia
Pierwszy przesłany
11 września 2015
Pierwszy przesłany, który spełnia kryteria kontroli jakości
11 września 2015
Pierwszy wysłany (Oszacować)
14 września 2015
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
23 października 2018
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
24 września 2018
Ostatnia weryfikacja
1 września 2018
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- 1064-003
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
TAk
Opis planu IPD
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Badanie danych/dokumentów
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .